tiprankstipranks
Cellectar Biosciences (CLRB)
NASDAQ:CLRB

Cellectar Biosciences (CLRB) Stock Price & Analysis

1,139 Followers

CLRB Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.25 - $3.15
Previous Close$2.57
Volume271.31K
Average Volume (3M)743.65K
Market Cap
$31.58M
Enterprise Value$27.01M
Total Cash (Recent Filing)$5.15M
Total Debt (Recent Filing)$584.50K
Price to Earnings (P/E)-0.7
Beta1.84
Mar 19, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.48
Shares Outstanding12,288,325
10 Day Avg. Volume175,888
30 Day Avg. Volume743,655
Standard Deviation0.20
R-Squared0.09
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-17.08
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.85
Forecast
Price Target Upside191.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2


Financials

Annual

Ownership Overview

0.00%
Insiders
1.90% Mutual Funds
10.15% Other Institutional Investors
87.95% Public Companies and
Individual Investors

CLRB FAQ

What was Cellectar Biosciences’s price range in the past 12 months?
Cellectar Biosciences lowest stock price was $1.25 and its highest was $3.15 in the past 12 months.
    What is Cellectar Biosciences’s market cap?
    Currently, no data Available
    When is Cellectar Biosciences’s upcoming earnings report date?
    Cellectar Biosciences’s upcoming earnings report date is Mar 19, 2024 which is in 107 days.
      How were Cellectar Biosciences’s earnings last quarter?
      Cellectar Biosciences released its earnings results on Nov 02, 2023. The company reported -$1.21 earnings per share for the quarter, missing the consensus estimate of -$0.57 by -$0.64.
        Is Cellectar Biosciences overvalued?
        According to Wall Street analysts Cellectar Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Cellectar Biosciences pay dividends?
          Cellectar Biosciences does not currently pay dividends.
          What is Cellectar Biosciences’s EPS estimate?
          Cellectar Biosciences’s EPS estimate is -$0.54.
            How many shares outstanding does Cellectar Biosciences have?
            Cellectar Biosciences has 12,288,325 shares outstanding.
              What happened to Cellectar Biosciences’s price movement after its last earnings report?
              Cellectar Biosciences reported an EPS of -$1.21 in its last earnings report, missing expectations of -$0.57. Following the earnings report the stock price went up 0.84%.
                Which hedge fund is a major shareholder of Cellectar Biosciences?
                Among the largest hedge funds holding Cellectar Biosciences’s share is Consonance Capital. It holds Cellectar Biosciences’s shares valued at N/A.

                  ---

                  Cellectar Biosciences Stock Smart Score

                  6
                  Neutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  Learn more about TipRanks Smart Score

                  Company Description

                  Cellectar Biosciences

                  Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June,1996 and is headquartered in Florham Park, NJ.

                  ---

                  Top 5 ETFs holding CLRB

                  Name
                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  $241.28K
                  8
                  iShares Core S&P Total U.S. Stock Market ETF
                  $12.35
                  8
                  Up to five ETFs with an Outperform Smart Score that hold CLRB. The ETFs are listed according to market value of CLRB within the ETF

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Adverum Biotechnologies
                  Arcturus Therapeutics
                  G1 Therapeutics
                  Krystal Biotech

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis